Domain antibodies: proteins for therapy

Area of Science:

• Biotechnology
• Immunology
• Protein Engineering

Background:

• Domain antibodies (dAbs) are naturally occurring fragments of heavy chain immunoglobulins found in camelids.
• They represent the smallest known antigen-binding antibody fragments, with molecular weights between 11 kDa and 15 kDa.
• dAbs are derived from the variable regions of heavy (VH) and light (VL) immunoglobulin chains.

Purpose of the Study:

• To describe the characteristics and potential applications of domain antibodies (dAbs).
• To highlight the advantages of dAbs in biopharmaceutical development.
• To emphasize their suitability for in vitro selection and therapeutic formatting.

Main Methods:

• Production of fully human domain antibodies (dAbs).
• High-level expression in microbial cell culture systems.
• Characterization of biophysical properties, including solubility and thermal stability.
• Application of in vitro selection systems, such as phage display, for affinity maturation.

Main Results:

• Domain antibodies (dAbs) exhibit favorable biophysical properties, including excellent solubility and temperature stability.
• They demonstrate high expression levels in microbial cell cultures.
• dAbs are effective as monomers and can be engineered into larger formats.

Conclusions:

• Domain antibodies (dAbs) are robust, small-sized antibody fragments with significant therapeutic potential.
• Their inherent stability and ease of production make them highly suitable for drug development.
• dAbs can be formatted to achieve prolonged serum half-lives and other desired pharmacological activities.